financetom
Business
financetom
/
Business
/
Food distributor Sysco cuts annual forecasts on weak restaurant traffic
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Food distributor Sysco cuts annual forecasts on weak restaurant traffic
May 25, 2025 8:54 PM

(Reuters) -Sysco's ( SYY ) third-quarter results missed estimates and the company lowered its annual forecasts on Tuesday as the food distributor warned of worsening consumer sentiment against the backdrop of the Trump administration's tariffs.

The company added that the wildfires in California and bad weather conditions also weighed on demand for supply of fresh fruits, vegetables and meat products to restaurants.

Sysco's ( SYY ) customers include restaurant chains KFC, Subway, Burger King and Applebees.

An anticipated surge in product prices following U.S. President Donald Trump's tariff policies on trading partners is expected to affect restaurant traffic, with people opting to eat more at home.

The levies and the retaliatory tariffs also pose a threat to Sysco's ( SYY ) international operations. The company's Canada operations accounted for about 8% of the company's annual sales in 2024.

The company, meanwhile, has been making efforts to source raw materials from suppliers at lower prices and keep production costs in check.

Sysco ( SYY ) now expects fiscal 2025 sales to increase about 3%, compared with prior expectations of it to grow between 4% and 5%.

The company also forecast full-year adjusted earnings per share to rise by at least 1%, compared with the previous forecast of 6% to 7% growth.

Sysco's ( SYY ) third-quarter sales rose 1.1% to $19.6 billion, compared with the average analyst estimate of $20.04 billion, according to data compiled by LSEG.

On an adjusted basis, the company earned 96 cents per share, missing expectations of $1.03.

(Reporting by Neil J Kanatt in Bengaluru)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2025 - www.financetom.com All Rights Reserved